Introduction {#s1}
============

Cardiac tumors can be classified into primary and secondary (metastatic). Primary cardiac tumors are extremely rare with an incidence of 0.001-0.03% based on the autopsy findings \[[@R01]\]. Approximately 75% of primary cardiac tumors are benign with 50% of those being myxomas, and the remaining being fibroelastoma, lipoma, fibroma, hemangioma, rhabdomyoma, paraganglioma and teratoma \[[@R01]-[@R03]\]. The remaining 25% of primary cardiac tumors are malignant with sarcomas accounting for 95% and lymphomas accounting for 5% of these tumors \[[@R01]\]. The most common cardiac sarcoma is the angiosarcoma (37%), while others include undifferentiated sarcoma (24%), malignant fibrous histiocytoma (11-24%), leiomyosarcoma (8-9%) and osteosarcoma (3-9%) \[[@R01]\]. Cardiac intimal sarcoma is the least reported type of primary cardiac sarcoma \[[@R01], [@R04]-[@R06]\]. However, a recent retrospective analysis by Neuville et al, showed cardiac intimal sarcomas (42%) to be the most frequent primary cardiac sarcoma followed by angiosarcoma (26%), undifferentiated sarcoma (22%), synovial sarcomas (7%), leiomyosarcomas (2%) and peripheral neuroectodermal tumor (1%) \[[@R07]\]. Cardiac intimal sarcomas are encountered more commonly in the large arterial blood vessels including pulmonary artery and aorta, and are extremely rare in the heart \[[@R04], [@R08]-[@R12]\].

Secondary or metastatic cardiac tumors are 20 - 40 times more common than the primary cardiac tumors \[[@R13]\]. Most common malignant neoplasms that metastasize to the heart and pericardium include lung and breast cancer \[[@R13]\]. Others malignancies, such as Hodgkin's and non-Hodgkin's lymphoma, malignant melanoma, various primary gastrointestinal malignant neoplasms, thyroid and renal neoplasms, and extracardiac sarcomas, can also involve the heart secondarily \[[@R14]\]. Here, we report a case of primary cardiac intimal sarcoma presenting with functional mitral stenosis and heart failure.

Case Report {#s2}
===========

A 66-year-old Caucasian female with past medical history of hypertension, hyperlipidemia and hypothyroidism presented to the emergency department with complaints of progressive exertional dyspnea for the last couple of months which had worsened in the last 2 days. She also had associated orthopnea, paroxysmal nocturnal dyspnea (PND) and exercise intolerance. The patient was hemodynamically stable on presentation with blood pressure of 108/75 mm Hg, pulse rate of 98/min, temperature of 97.2 °F, respiratory rate of 16 cycles/min and SpO~2~ of 98%. Cardiovascular system examination revealed normal S1 and S2 without any murmurs, gallops or rubs with mild jugular venous pressure (JVP) elevation, and respiratory system exam was significant for bilateral crackles. Laboratory data are presented in [Table 1](#T1){ref-type="table"}. The results of hepatic panel, renal function and lipid panel were within normal limits. An electrocardiogram showed normal sinus rhythm with occasional premature ventricular complexes ([Fig. 1](#F1){ref-type="fig"}). She was hospitalized for suspected new-onset decompensated congestive heart failure and also to rule out pulmonary embolism in view of acute onset of dyspnea. Contrast CT chest (pulmonary embolism protocol) showed no evidence of pulmonary embolism, but revealed small bilateral pleural effusion and diffuse pulmonary edema ([Fig. 2](#F2){ref-type="fig"}).

###### Initial laboratory results

  --------------------------------------------- --------------------------------------------------
  Complete blood count                          
    White blood cells                           10.7 × 10^3^/cmm (4.4 × 10^3^ - 9.7 × 10^3^/cmm)
    Hemoglobin                                  12.5 g/dL (13.2 - 17.4 g/dL)
    Red blood cells                             3.86 mil/cmm (4.22 - 5.8 mil/cmm)
    Hematocrit                                  37.6% (39.6-50.7%)
    Platelet count                              302 thou/cmm (150 - 370 thou/cmm)
    Mean corpuscular volume                     97.4 fl (80 - 100 fl)
    Mean corpuscular hemoglobin concentration   33.2% (31.9-35.6%)
    Red cell distribution width                 12.4% (11.8-14.5%)
    Mean corpuscular hemoglobin                 32.0 pg (27.4 - 32.8 pg)
  Basic metabolic panel                         
    Serum sodium                                141 mEq/L (136 - 145 mEq/L)
    Serum potassium                             3.4 mEq/L (3.5 - 5.1 mEq/L)
    Serum chloride                              104 mEq/L (98 - 107 mEq/L)
    Serum bicarbonate                           28 mEq/L (21 - 32 mEq/L)
    Serum creatinine                            0.88 mg/dL (0.67 - 1.17 mg/dL)
    Blood urea nitrogen                         16 mg/dL (7 - 18 mg/dL)
    Blood glucose                               133 mg/L (70 - 99 mg/dL)
    Serum calcium                               9.1 mg/dL (8.5 - 10.1 mg/dL)
    Serum magnesium                             2.1 mEq/L (1.5 - 2 mEq/L)
    Anion gap                                   12 mEq/L (8 - 16 mEq/L)
  Hepatic panel                                 
    Aspartate aminotransferase                  26 IU/L (5 - 30 IU/L)
    Alanine aminotransferase                    22 IU/L (5 - 30 IU/L)
    Total bilirubin                             18 µmol/L (2 - 20 µmol/L)
    Direct bilirubin                            2 µmol/L (0 - 6 µmol/L)
    Serum albumin                               4 g/dL (3.5 - 5.5 g/dL)
    Total protein                               7.5 g/dL (6 - 8.3 g/dL)
  Cardiac markers                               
    Creatinine kinase                           28 U/L (25 - 200 U/L)
    Creatinine kinase-MB                        22 IU/L (5 - 25 IU/L)
    Serum troponin (initial on presentation)    \< 0.015 ng/mL (0.015 - 0.045 ng/mL)
    Serum troponin (second at 3 h)              \< 0.015 ng/mL (0.015 - 0.045 ng/mL)
    Serum troponin (third at 6 h)               \< 0.015 ng/mL (0.015 - 0.045 ng/mL)
  --------------------------------------------- --------------------------------------------------

![Electrocardiogram showing normal sinus rhythm with occasional premature ventricular complexes.](cr-09-307-g001){#F1}

![Computed tomography chest (pulmonary embolism protocol). (a) Small bilateral pleural effusions with diffuse pulmonary edema; (b) normal sized heart without pericardial effusion.](cr-09-307-g002){#F2}

Diuretic therapy with furosemide was initiated for symptomatic relief. Transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE) revealed an enlarged left atrium with a 4 × 4 cm multi-lobed mobile mass, causing severe functional stenosis and mitral regurgitation with mild-to-moderate pulmonary hypertension ([Figs. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Cardiac magnetic resonance imaging (MRI) showed a large oval echodensity measuring 4.1 × 3.4 cm within the left atrium and appeared to be attached to the posterior mitral leaflet prolapsing during diastole ([Fig. 5](#F5){ref-type="fig"}). The most likely differential for this mass included a large myxoma, although a thrombus could not be fully excluded. Other differentials were lymphoma, angiosarcoma and melanoma given the mass originating away from the inter-atrial septum, unlike most of the myxomas. Cardiothoracic surgery was consulted for recommendations on tumor excision. The tumor was excised with negative margins, utilizing cardiopulmonary bypass. There were no significant postoperative complications except for paroxysmal atrial fibrillation and the patient was discharged home. Subsequent histopathology showed intimal sarcoma grade 3 with negative surgical margins ([Fig. 6](#F6){ref-type="fig"}). The tumor size was approximately 5.5 × 4.5 × 2.5 cm and mitotic activity was approximately 3/10 hpf with prominent tumor necrosis (\> 50%). The surgery was considered to be the definitive treatment as preoperative cardiac MRI and chest CT showed no evidence for metastasis.

![Transthoracic echocardiogram showing large mobile density within left atrium. (a) Moving into mitral annulus during diastole; (b) mass seen in left atrium during the systole.](cr-09-307-g003){#F3}

![Transesophageal echocardiogram showing multilobed mobile large left atrial mass. (a) Mass attached above posterior mitral valve leaflet, which prolapses into left ventricular inflow during diastole; (b) mass seen in the left atrium during systole.](cr-09-307-g004){#F4}

![Magnetic resonance imaging of myocardium with and without contrast demonstrating characteristics of the mass. (a) Large oval echodensity measuring 4.1 × 3.4 cm visualized within the left atrium on TRU FISP cine imaging, with possible attachment to the posterior mitral leaflet. (b) Isotense on T1-weighed spin echo imaging. (c) No enhancement of mass with first pass of gadalonium. (d) Lack of late gadolinium enhancement of mass.](cr-09-307-g005){#F5}

![Histopathology pictures of cardiac intimal sarcoma showing cells arranged in spindles with high mitotic activity. (a) H&E stain showing extensive necrosis; (b) H&E stain showing abundant blood vessels; (c) H&E stain showing mitotic activity approximately 3/10 hpf and prominent tissue necrosis; (d) negative tumor margins.](cr-09-307-g006){#F6}

Discussion {#s3}
==========

This is a rare case of primary cardiac intimal sarcoma presenting with functional mitral stenosis and heart failure. Cardiac intimal sarcomas are endocardial mesenchymal tumors that most commonly arise from great vessels like the pulmonary artery or thoracic aorta and are rarely seen in the heart with most originating in the left heart \[[@R07], [@R08]\]. Like in our case, cardiac intimal sarcomas are common in women older than 40 years of age and about 65% of those that arise in the heart originate from the left atrium away from the septal wall unlike most of the myxomas that originate from the inter-atrial septum \[[@R07]\]. Signs and symptoms of these tumors result from intracardiac obstruction and hence depend on their site, size, invasiveness, friability and the rate of tumor growth \[[@R12]\]. Although constitutional symptoms are not uncommon, which include fever, fatigue and weight loss, our patient did not have any of these symptoms. Affected individuals may also present with signs of systemic embolization, splenic and renal infarct, transient ischemic attacks and strokes \[[@R12]\]. Other uncommon presentations include atrial fibrillation and other conduction abnormalities, pericardial effusion, signs and symptoms from metastasis; pulmonary metastases (40%) and extrathoracic metastasis (20%) involving kidneys, lymphnodes, brain and skin \[[@R12]\]. Patients may also be asymptomatic until later stages of the disease \[[@R08]\]. TTE, TEE, CT scan and cardiac MRI may aid in the diagnostic process; however, definitive diagnosis is established by histopathology \[[@R11]\]. Most cardiac sarcomas demonstrate some degree of late gadolinium enhancement on MRI, however, there was lack of late gadolinium enhancement in our case which is unusual.

Different histological subtypes of cardiac sarcomas include, but are not limited to, angiosarcoma, leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma, synovial sarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma and intimal sarcoma \[[@R07]\]. Cardiac intimal sarcoma (spindle cell tumor) is extremely rare and underreported among all cardiac tumors of the heart, and is associated with very poor prognosis. In up to 25% of the cases, cardiac intimal sarcomas could histologically mimic myxofibrosarcoma, synovial sarcoma, epitheloid leiomyosarcoma or sarcoma with rhabdoid differentiation \[[@R07]\]. Undifferentiated cardiac intimal sarcomas demonstrate atypical and tightly packed spindle-shaped cells arranged in long fascicles, areas of necrosis, cellular atypia and nuclear polymorphisms \[[@R12]\]. Furthermore, genomic profiling shows recurrent 12q13-14 amplicon involving MDM2, 4q12 amplicon involving KIT and PDGFRA, 7p12 gain involving EGFR and 9p21 deletion targeting CDKN2A \[[@R07]\]. Immunohistochemistry is generally positive for HMGA 2, CDK4, vimentin, osteopontin and MDM2; however, MDM2 overexpression and amplification confirmation by FISH, qPCR or aCGH is the pathognomonic finding in differentiating intimal sarcoma from other histological subtypes of cardiac sarcomas \[[@R07]\]. CD31, CD34 and factor VIII are typically negative, but may be positive in areas with angiosarcomatous differentiation \[[@R12]\].

The mainstay of treatment for cardiac intimal sarcomas includes achievement of tumor-free margins with surgical resection, which is associated with improved survival \[[@R12]\]. The average mean life expectancy is 3 - 12 months \[[@R06]\]. The life expectancy is twice as long for patients who undergo complete tumor resection, which indicates that early diagnosis and treatment have important prognostic and therapeutic implications \[[@R15]\]. Often cardiac intimal sarcomas recur locally and metastasize early in less than 1 year \[[@R08]\]. Genomic analysis showing frequent alteration in genes like MDM2, PDGFRA and EGFR has led to further research on targeted therapeutic approach \[[@R07]\], thus, paving a way for other treatment modalities such as chemotherapy and radiation therapy for the treatment of cardiac intimal sarcomas \[[@R08]\]. Chemotherapy regimens that may have survival benefit in cardiac intimal sarcoma patients include, ifosfamide-epirubicin (or doxorubicin) and CyVADIC (cyclophosphamide, vincristine, doxorubicin and dacarbazine), which are mainly used for soft tissue sarcomas \[[@R16]\]. Gemcitabine-based chemotherapy regimen (single agent or in combination with docetaxel) can be tried as well due to the positive response observed in patients with soft tissue sarcomas \[[@R08], [@R17], [@R18]\]. Tyrosine kinase inhibitor such as pazopanib targeting PDGFRA can be considered for advanced disease, especially in patients who are refractory to the above drugs \[[@R08]\]. In 2012, results of the PALETTE trial lead to the approval of pazopanib in the USA for use in advanced non-adipocytic soft tissue sarcomas of patients who have had prior chemotherapy \[[@R08], [@R19]\]. The PALETTE trial results showed overall survival of 12.5 months (10.6 - 14.8) with pazopanib versus 10.7 months (8.7 - 12.8) with placebo (HR: 0.86, range: 0.67 - 1.11; P = 0.25) \[[@R19]\].

Complications of cardiac intimal sarcoma include heart failure, arrhythmias, heart block, valvular regurgitation, cardiac rupture, sudden cardiac death and pericardial effusion with or without tamponade \[[@R20]\]. Factors that are associated with worse prognosis include necrosis, high mitotic count, metastasis and anatomical location of the tumor within the heart (intracavitary versus intramural) \[[@R11], [@R12]\]. Left-sided tumors usually carry a better prognosis than right-sided tumors. Most patients have metastatic disease; 80% die within 1 year \[[@R11]\]. Patients with complete tumor resection are known to live twice as long as those without the surgical resection \[[@R15]\]. There are no current definite guidelines on follow-up, but patients diagnosed with high-grade cardiac intimal sarcoma will need closer monitoring due to the high rate of recurrence.

Conclusions {#s3a}
-----------

Cardiac intimal sarcomas are extremely rare and remarkably aggressive primary malignant tumors of the heart with poor prognosis. The presentation is quite variable and needs high degree of clinical suspicion for timely diagnosis and intervention, which has a great impact on the prognosis. The mainstay of treatment for cardiac intimal sarcomas is achievement of tumor-free margins with surgical resection, which is associated with improved survival.
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